Division of Urology, Department of Regenerative and Transplant Medicine, Graduate School of Medical and Dental Sciences, Niigata University, Asahimachi 1, Niigata 951-8510, Japan.
Ther Adv Urol. 2013 Apr;5(2):111-9. doi: 10.1177/1756287212461681.
Naftopidil, which to a certain extent shows an affinity to α1D-adrenoceptor subtype in addition to a high affinity to α1A-adrenoceptor, has been used for the treatment of benign prostatic obstruction and benign prostatic hyperplasia (BPH) associated lower urinary tract symptoms (LUTS). The aim of the present review is to systematically refer to the published studies on this unique agent for BPH. Based on a randomized prazosin-controlled study and another double-blind placebo-controlled study, which verified the dose-dependent effects of naftopidil, the Japanese Ministry of Health, Labor and Welfare approved naftopidil for treating men with BPH in 1996. Several tamsulosin-controlled studies have suggested treatment effects of naftopidil similar to those of tamsulosin and potentially higher efficacy for alleviating storage symptoms by naftopidil. Although well-designed, randomized studies are warranted to confirm the long-term outcomes and effector/target of naftopidil, the α1A-antagonist naftopidil, which also blocks α1D-adrenoceptor, improves voiding symptoms, and may also be useful for the management of men with storage symptoms represented by nocturia, retrieving their quality of life impaired by BPH-associated LUTS.
那夫哌地尔除了对α1A-肾上腺素受体具有高亲和力外，还对α1D-肾上腺素受体具有一定的亲和力，已被用于治疗良性前列腺增生（BPH）和良性前列腺增生相关的下尿路症状（LUTS）。本综述的目的是系统地查阅关于该独特药物治疗 BPH 的已发表研究。基于一项随机哌唑嗪对照研究和另一项双盲安慰剂对照研究，验证了那夫哌地尔的剂量依赖性效应，日本厚生劳动省于 1996 年批准那夫哌地尔用于治疗 BPH 男性。几项坦索罗辛对照研究表明，那夫哌地尔的治疗效果与坦索罗辛相似，并且那夫哌地尔可能通过缓解储存症状具有更高的疗效。尽管需要进行精心设计的随机研究来确认那夫哌地尔的长期结果和作用靶点，但作为α1A-拮抗剂的那夫哌地尔也可以阻断α1D-肾上腺素受体，改善排尿症状，对于治疗以夜尿为代表的储存症状的男性也可能有用，改善他们因 BPH 相关 LUTS 而受损的生活质量。
